Global assembling of Academicians, Researchers, Scholars & Industry to disseminate and exchange information at 100+ Allied Academics Conferences

Elucidating Mycobacterial Resistance & Driving sustainability for disease control
- Tuberculosis 2017


Thanks to all of our wonderful Speakers, Conference Attendees and Collaborators; Tuberculosis 2017 Conference was completed successfully.

Global summit on Tuberculosis and Lung Disease hosted by Allied Academies was successfully held during September 20-21, 2017 at Double Tree by Hilton Philadelphia Airport, USA with the theme “Elucidating Mycobacterial Resistance & Driving sustainability for disease control”.

The Conference was marked with the presence of renowned scientists, talented young researchers, students and delegates from all around the world driving the event into the path of success. With the support and guidance of Organizing Committee Members and astonishing presentations of all participants this prominent event became more impressive. It also provided invaluable networking opportunity, deploying the foundation for new research endeavors and development projects.

The meeting was carried out through varied sessions, in which the discussions were held on the following major scientific tracks:

Re-emergence of Tuberculosis

Epidemiology of disease

M. tuberculosis Genetics

Virulence of M. tuberculosis


Mycobacterial infections

Lung Infection

Respiratory Tract Infections

Pulmonary Disease and Therapeutics

Bronchial Asthma

Diagnostic Techniques of Lung Disorders

Immunization & Vaccines

TB & HIV co-infections

Preventive Approaches for TB

Challenges in TB Diagnosis

Clinical Trials- TB

TB drug Resistance

Allied Academies would like to convey a great appreciation to following eminent people, honourable guests and Keynote speakers.

Joan-Miquel Balada-Llasat, Ohio State University, USA

Shu-Hua Wang, Ohio State University, USA

Dr. Ruxana T Sadikot, Emory University, USA

Seyed Ehtesham Hasnain, Jamia Hamdard University, India

Benjamin Lawson, Honor Health Medical Centre, USA

Karla Kohan-Ivani, Institute of Public Health, Chile

Arun Nachiappan, University of Pennsylvania, USA

Shashank Gupta, Brown University, USA

Shaleen B. Korch, Midwestern University, USA

Stefano Rigotti, Sacro Cuore Negrar, Italy

Mizu Nonaka, Ibaraki Higashi National Hospital, Japan

Jashandeep Kaur, Panjab university, India

Bandana Kumari, Panjab university, India 

With the success of Tuberculosis 2017, Allied Academies is proud to announce the 2nd Annual summit on Tuberculosis and Lung Disease to be held during July 16-17, 2018 in Atlanta, USA with the theme “A new way to battle with Tuberculosis and Lung disease”.

We hope your favourable support will make next annual also one more grand success event.



Allied Academic Publication is a union of several esteemed academic and scientific associations known for promoting scientific journals. Established in the year 1997, Andrew John Publishing Group is a specialized Medical publisher that operates in alliance with the association and societies.  This publishing house has been built on the base of esteemed academic and research institutions including The Canadian Vascular Access Association (CVAA), The College of Audiologists & Speech Language Pathologists of Ontario(CASLPO), The Association for Public Safety Communications Officials of Canada (APCO), The Canadian Society of Internal Medicine (CSIM), The Canadian Association of Neurophysiologic Monitoring (CANM). The Canadian Hard of Hearing Association (CHHA), Sonography Canada, Canadian Association of Pathologists (CAP-ACP).

Allied Academies give the opportunity to meet the main experts around the world and invites participants all around the world to attend “Global Summit on Tuberculosis and Lung Diseases” during September 20-21, 2017 in Philadelphia, USA, which includes prompt Keynote Presentations, Oral talks, Special Sessions, Symposiums, Poster Presentations, Workshops and Exhibitions.




Track 01: Re-Emergence of Tuberculosis

Tuberculosis is a highly contagious airborne disease caused by the bacteria “Mycobacterium tuberculosis”. Mycobacterium is an obligate pathogenic bacteria and the causative agent of tuberculosis.  M. tuberculosis is highly aerobic and requires high levels of oxygen. Mycobacteria are non-motile, non-capsulated and non-sporing. It was first discovered by Robert Koch, in 1882.M. tuberculosis has an unusual, waxy coating on its cell surface, due to the presence of mycolic acid, which makes the cells unaffected to Gram staining. M. tuberculosis can appear Gram- positive and Gram- negative in clinical settings. The acid-fast stain, Ziehl-Nelsen stain or by fluorescent dyes is used preferably. In liquid cultures they form a mold -like pellicle, hence the name “Mycobacteria”, meaning fungus like bacteria. The most frequently used diagnostic methods for tuberculosis are the tuberculin skin test, acid-fast stain, and chest radiographs.

Track 02: Epidemiology of the Disease

Tuberculosis epidemiology is the field of science that is concerned with the study of health and disease within populations and the various factors that lead to these conditions, with a goal of preventing the spread of disease. One-third of the world's population has been infected with M. tuberculosis. Anyhow, not all infections with M. tuberculosis lead to TB disease. 13.7 million Chronic active cases, were reported by 2007 and 8.8 million new cases were estimated in 2010 and 1.45 million deaths, are often noted in developing countries.  Out of these, 0.35 million deaths occur in those co-infected with HIV. Tuberculosis distribution is not symmetrical across the globe, in many African and Asian countries (about 80% of the population) test positive in tuberculin tests, and in U.S only 5–10% of the population test positive. In 2012, around 450,000 people developed MDR-TB. TB incidence varies with age. In Africa, TB chiefly affects adolescents and young adults. However, in United States, TB has gone from high to low incidence, where TB is mainly a disease of older people, or of the immunosuppressed.

Track 03: Genetics of M. tuberculosis

In 1998, the genome of the H37Rv strain was published. The size of the genome is 4 million base pairs, and has 3959 genes, out of these 40% of genes have their function characterised and another 44% are postulated with possible functions. Six pseudo genes are present within the genome.

Genome contains 250 genes involved in fatty acid metabolism, with 39 of these involved in the polypeptide metabolism generating the waxy coat. Such vast numbers of conserved genes show the revolutionary importance of the waxy coating to pathogen survival. M. tuberculosis can grow on the lipid cholesterol as a sole source of carbon, as genes involved in the cholesterol use pathways that have been important during various stages of the infection with tuberculosis. Mycobacteria that are isolated from lungs of infected mice were shown to use fatty acids over carbohydrate substrates, especially during the chronic phase of infection when other nutritional sources are not available.

10% of the coding genes are taken up by the amino acids that encode acidic, glycine-rich proteins. These proteins have a conserved N-terminal motif, deletion of which leads to impaired growth in granulomas and macrophages

Track 04: Virulence of M. tuberculosis

When the mycobacteria reach the pulmonary alveoli, TB infection begins. The bacteria start invading and replicating within endosomes of alveolar macrophages. Macrophages analyse the bacterium as foreign and try to eliminate the bacteria by phagocytosis. During this process, the mycobacterium is surrounded by the macrophage and placed impermanently in a membrane-bound vesicle called phagosome. The phagosome then associates with lysosome to form phagolysosome. In the phagolysosome, the cell intends to use acid and reactive oxygen species to kill the bacterium. However, M. tuberculosis has a broad, waxy coating of mycolic acid that protects the cell from these toxic substances. M. tuberculosis has the ability to multiply and reproduce inside the macrophage until they burst the macrophage and will finally kill the immune cell, which leads to further infection.

The primary site of infection in lungs, is known as the "Ghon focus", is either located in the lower part of the upper lobe or in the upper part of the lower lobe. Infection through the blood stream may also cause, tuberculosis of the lungs. This is known as Simon focus and is generally found in the upper part of the lungs. The hematogenous transmission may also spread infection to other sites, such as the brain, kidneys, peripheral lymph nodes, and to the bones. Other parts of the body may also be affected by the disease, it may rarely affect the pancreas, heart, thyroid or skeletal muscles.

Track 05: COPD

COPD is a disease involving airway inflammation and thickening. It also involves the destruction of oxygen-exchanged lung tissue. The Global Initiative for Chronic Obstructive Pulmonary Disease is described as "preventable and treatable disease, characterized by an incompletely reversible airflow limitation, which is usually progressive and is associated with an abnormal inflammatory response to harmful particles or gases. This gradual and relentless loss of lung disease is caused by emphysema caused by the destruction of the lung parenchyma. Smoking (long term smokers), chronic bronchitis, genetic factors (genes) and due to chronic inflammation and fibrosis as well as elasticity The resulting loss of small airway narrows, which leads to gradual airflow limitation, air capture, and further shortages of breathing in motion.

Track 06: Mycobacterial infections

Tuberculosis is a chronic inflammatory infectious disease caused by the bacteria, Mycobacterium tuberculosis. Tuberculosis generally affects the lungs, but can even affect other parts of the body. Most infections are asymptomatic, known as latent tuberculosis. About 10% of latent infections progress to active disease, if left untreated, mostly kills about half of those infected. Symptoms of active TB are chronic cough with blood-containing sputum, night sweats, one weight loss and fever. Infection of other organs can cause a wide range of symptoms including bones and joint pains, chest pain, neurological disorders and chronic pulmonary or respiratory distress etc.

Ø  People with reduced immune systems are at highest risk of producing active tuberculosis and dying of the disease, people infected with HIV are 40 times more likely to develop TB.

Ø  Tuberculin is the mostly used skin test for diagnosis of TB.

Ø  Some antibiotics fail to kill the bacteria completely, as the bacterium becomes resistant to those antibiotics.  A majority of TB cases can be treated with antibiotics, such as isoniazid and rifampicin, which are the most powerful, anti-TB drugs.

Ø  Fully complete course of DOT treatment can successfully eradicate the infection and reduce the risk of antibiotic resistance developing.

Track 07: Lung infection

A Lung infection affects lungs, either in the larger airways (bronchitis) or in the smaller air sacs (pneumonia). There is a build-up of pus and fluid (mucus), and the airways become swollen, making it difficult for you to breathe. Chest infections can affect people of all ages. Young children and the elderly are most at risk, as well as people who are ill and smokers. A chest infection can be serious for these people.

Track 08: Respiratory Tract Infections

The main respiratory tract is infected with sinusitis, throat and airway or lung. They are generally caused by viruses or bacteria, mainly people visit their general doctors and pharmacists because the cold is the most popular RTI. In general, health professionals maintain the distance between upper respiratory tract infections, which are affected by sinus and throat, and the other is respiratory infections, which are the effects of the respiratory tract and the lungs. RTI mainly affects children as adults, because they do not have more immunity to resistance, and many viruses can cause these lung infections. Whenever you sneeze or cough, if these people breathe, they will be infected. Even if someone encounters your surface or any object, the virus may pass through someone else to avoid these types of lung infections, and you must regularly clean your hands with soap or warm water.

Track 09: Pulmonary Diseases and Therapeutics

According to market criteria, we have advanced diagnostic techniques such as X-ray and echocardiography to diagnose and identify lung cancer and lung function tests (PFT) is another test to determine lung cancer disease. This is a medical process involving the pleural cavity and other thoracic internal examination, biopsy and resection of the disease or mass. Thoracoscopy may be sedation under general anesthesia or local anesthesia. Surgical biopsy is a better way to diagnose lung cancer standards. We must wear appropriate masks and monitor exposure, and in some working environments it is important to take precautions. Chronic obstructive pulmonary disease is a gradual process that causes difficulties in the death of respiratory failure or its associated lung disease (including respiratory arterial disease, lung cancer, stroke and smoking cessation), and is the process of stopping smoking. Tobacco contains nicotine, which is addictive; in the process of smoking cessation, we can control by vaccination and prophylaxis.

Track 10: Bronchial Asthma

Asthma is a chronic disease when you breathe when it makes your lungs harder Asthma cannot be cured, but the treatment is better, people can control and live their lives. The effect of asthma on the airway wall is swelling or inflammation. Respiratory infections are inflated, making the respiratory tract very sensitive and stimulating, increasing your sensitivity to any response. This may cause your airway to be narrow, and the lungs have very little air through them. The main symptoms of asthma are wheezing and chest pain, difficulty breathing, high coughing, which usually occurs at night and early in the morning.

Track 11: Diagnostic Techniques of Lung Disorders  

According to market criteria, we have advanced diagnostic techniques such as X-ray and echocardiography to diagnose and identify lung cancer and lung function tests (PFT) is another test to determine lung cancer disease. This is a medical process involving the pleural cavity and other thoracic internal examination, biopsy and resection of the disease or mass. Thoracoscopy may be sedation under general anesthesia or local anesthesia. Surgical biopsy is a better way to diagnose lung cancer standards. We must wear appropriate masks and monitor exposure, and in some working environments it is important to take precautions. Chronic obstructive pulmonary disease is a gradual process that causes difficulties in the death of respiratory failure or its associated lung disease (including respiratory arterial disease, lung cancer, stroke and smoking cessation), and is the process of stopping smoking. Tobacco contains nicotine, which is addictive; in the process of smoking cessation, we can control by vaccination and prophylaxis.

Track 12: Vaccines & Immunization

As of 2011, the only available vaccine is Bacillus Calmette-Guérin (BCG), is a vaccine for (TB) tuberculosis disease. Many people have been BCG-vaccinated. BCG is primarily used as vaccine in many countries with a high aid for preventing TB as childhood tuberculous meningitis and miliary disease. Tuberculosis can be treated by taking several drugs for 6 to 9 months.  There are 10 drugs presently approved by FDA (U.S. Food and Drug Administration) for treating TB. Out of the approved drugs, the first-line anti-TB agents that form the basis of treatment regimens include: isoniazid, pyrazinamide rifampin, ethambutol, streptomycin. Once the TB patient is known to be fully susceptible to ethambutol or streptomycin, it can be discontinued.

Directly observed therapy (DOT) is mainly recommended for all the patients. With DOT treatment, patients with the above regimens can shift to 2 to 3 times per week dosage after an initial 2 weeks of daily dosing. Patients on twice-weekly dosing should not miss any doses. Require daily therapy for patients on self-administered medication.

Track 13: TB Co-infections

TB and HIV co-infection is that where people have both, either latent or active TB disease and also HIV infection. A condition, where someone has both HIV and TB, each disease speeds up the progress of the other disease. In addition to HIV infection is speeding up the progress from latent TB infection to active TB disease, in accordance TB bacteria also enhance the progression of HIV infection. Than many other opportunistic infections, TB occurs earlier in the course of HIV infection. In co-infected individuals, the risk of death is also twice that of HIV infected individuals without TB, even when antiretroviral therapy and CD4 cell count are taken into account. The provision of anti TB drug therapy and HIV antiretroviral treatment at the same time involves a number of potential difficulties including: A high pill burden, Drug – drug interactions, Cumulative drug toxicities

TB and Diabetes co-infection: Poorly controlled diabetes can lead to numerous complications, including neuropathy, vascular disease, and increased susceptibility to infection. Diabetes may also lead to increased susceptibility to the disease via multiple mechanisms that are caused by M. tuberculosis. The mechanisms include those directly related to cellular insulinopenia and hyperglycaemia as well as indirectly effects on macrophages and lymphocyte function, leading to diminished strength to hold the organism.

There are even other co-infections with Tuberculosis such as malaria, Typhoid fever, Dengue, hepatitis.

Track 14: Preventive Approaches for TB

TB prevention and control efforts depend primarily on the vaccination of infants and the detection and treatment of active cases. The World Health Organization (WHO) has achieved some success with rapid diagnostics and improved treatment regimens. US Preventive Services Task Force (USPSTF) endorses screening those who are at high risk for latent tuberculosis with either Mantoux tuberculin skin tests or interferon- ? release assays.

TB education is very much important for the general public awareness. The public needs to know basic information about Tuberculosis for many reasons including their spread through air, reducing the stigma associated with Tuberculosis.

Prevention of TB consists of two main parts. The first part of preventing TB is to cease the transmission of Tuberculosis from one person to another. This can be done firstly, by identifying people with active TB infection, and then curing them by providing the drug treatment. With the provision of proper TB therapy someone with TB will not be infectious very quickly, and so cannot spread the disease to others. The second main part of preventing TB is to prevent people with latent TB infection from developing active infectious TB disease.

Track 15: Challenges in TB Diagnostics

Tuberculosis has been a disease touching almost all parts of the globe since ages. Many efforts or strategies came in the past for improving diagnosis and treatment.  An effective vaccine has been desired after for long. With the emergence of resistant strains of Mycobacterium tuberculosis, and complexities emerging due to various associated infections and disease conditions, there is a furious need for further research in the field. Be it the better medication and care or better resistance management, proper diagnostics holds the key to success. It has been observed that a huge burden of the disease was accompanied by poor research set-up and resource limitations. The scenario was the same for several decades. With the renewed vision of funding agencies and resourceful countries, funding has been provided in many areas of research in tuberculosis detection and treatment.

Track 16: TB Clinical Trials

Clinical trials are concerned with diagnosis and Treatment of the disease. The development of drug-resistant TB (XDR-TB) and multidrug-resistant TB (MDR-TB) are extensively a rising global health problem. A recent advance in the progress of new drugs & regimens provides hope that may be well effective, tolerated, and shorter-duration treatment for tuberculosis will become available. During clinical trials they promote research within local TB control programs through association on clinical research of importance to public health settings, and to provide a platform for international collective research of consequence to both domestic and universal TB control.

Rapid urine-based screening for Tuberculosis in hospitalised patients in Africa to reduce AIDS-related mortality. Thibela TB is the mass screening and treatment plan in mining communities, The ZAMSTAR trial is the community TB testing and counselling, Diabetes correlated with increased risk of TB in the United Kingdom are some of the latest clinical trials or the projects going-on to reduce the risk of Tuberculosis.

Track 17: Resistance to TB Drugs

Multidrug-resistant TB (MDR-TB) begins when an antibiotic fails to eradicate all the bacteria that it targets, with the surviving bacteria producing resistance to that antibiotic and usually others at the same time. Primary Multidrug resistant, MDR-TB occurs in patients who was not earlier been infected with TB but who became infected with a strain which is resistant to the treatment. Acquired multidrug resistance for TB occurs in patients during treatment with a drug regimen that is not competent of killing the particular strain of TB with which they have been infected. MDR-TB requires treatment with second-line drugs, often four or more anti-TB drugs for a minimum of 6 months and a maximum for 18–24 months, if rifampin resistance has been identified in the specific strain of TB with which the patient has been infected. Under ideal program conditions, MDR-TB cure rates can approach 70%. In general, second-line drugs are less effective, more toxic and much more expensive than first-line drugs. 

Market Analysis Report

Market Analysis report:

Health departments of Columbia (DC) verified TB cases in the 50 states and District electronically report that meet the Council of State, CDC and Territorial Epidemiological case defines to the National Tuberculosis Surveillance System. Reports involve the patient’s medical and demographic information, clinical information and social risk factors for TB, and about the TB case. CDC calculates state and overall national TB incidence by using July 1 midyear population estimates from the U.S. Census Bureau. The Current Population Survey provides the population figures for incidence according to race/ethnicity and national origin. TB case tally and incidence during 2015 as per 100,000 population and % change from 2014 were determined for 50 states and for each census division.

TB incidence in the United States during 2013–2015 remained approximately 3.0 cases per 100,000 persons. After 2 decades of progress toward tuberculosis elimination with annual decreases of ?0.2 cases per 100,000 persons have been reported. Initial data stated to the National Tuberculosis Surveillance System display that TB incidence among U.S.-born persons (1.2 cases per 100,000) has remained approximately 13 times the foreign-born persons incidence in the U.S (15.1 cases per 100,000). Proceeding to the progress towards TB elimination will require amassing of efforts both in the U.S and other parts of the world, including, strengthening systems to stop TB transmission in the United States and all around the universe, increasing U.S. efforts to detect and treat latent TB infection, and accelerating reductions in TB globally, particularly in the countries of origin and with highest reported cases.

  Notifications of respiratory tuberculosis cases and incidence to ESMI, 2000-2011*


Number of cases

Incidence (per 100,000 population)

Annual change in numbers (%)

Annual change in incidence (%)





























































*Data for 2010-11 are provisional and may be subject to change



FIGURE: Tuberculosis (TB) incidence overall and among U.S. and foreign-born persons, by year, 2000–2015*




 Societies and Associations:

           American Lung Association

          National Tuberculosis Controllers Association

           American Thoracic Society


·         AstraZeneca

·         Otsuka

·         Tibotec

·         Vertex

·         GlaxoSmithKline-Tres Cantos Medicines Development Campus

In 2009 the TB-TC (TB- treatment campaign) underwent its third formal external re-competition. In the next decade (2010–2020), TBTC patient enlistment will shift from clinical sites located mostly in North America to sites which are predominantly international. The 2009 championship has expanded TBTC’s international presence from a few clinical sites located outside of North America, to sites in Peru, Spain, South Africa (two sites), Uganda, Kenya, Vietnam, China (Hong Kong).The TBTC 2010–2020 research group also includes U.S. sites in New York, Washington DC, Texas (four sites), Colorado and Tennessee. Some TBTC sites in and outside North America are linked, in that CDC awarded funds for the international study sites to the U.S. based institutions that proposed them as partners in the competitive process.


TBTC clinical trials have enrolled more than 14,000 patients and volunteers over the past 20 years. The consortium's annual operating budget is approximately $9,000,000.00.Encounting many challenges to the successful development of new TB drugs and treatment regimens, the TBTC looks forward with optimism. The late plateform of new anti-TB drug candidates is the most promising in 40 years, and advances in TB clinical trials science have promoted the progress of these agents. With commitment and support from CDC, the TBTC provides a unique resource for these clinical studies, and will continue to play an important role in improving TB treatment, prevention and control. Currently the TBTC is conducting an international, multicenter, randomized, controlled, open-label, 3-arm, phase 3 non-inferiority trial. The results of this clinical trial determine the efficacy, using the definitive endpoint of durable cure, of a regimen containing rifapentine substituted for rifampin and administered in combination with other drugs for 17 weeks (approximately four months).   

Organizing Committee
OCM Member
Dr. Ruxana T Sadikot
Professor of Medicine, Pulmonary and Critical Care
Emory University
Atlanta, USA
OCM Member
Seyed Ehtesham Hasnain
President and Vice Chancellor , Molecular Medicine
Jamia Hamdard University
New Delhi, India
OCM Member
Dr. Arun Nachiappan
Professor of Clinical Radiology
University of Pennsylvania
Philadelphia, USA
Scientific Program
Renowned Speakers

Conference Dates: September 20-21, 2017

Double Tree by Hilton Philadelphia Airport 

4509 Island Ave, Philadelphia PA 19153 

Julie Rafine (sales manager)

Phone - 2159374510

Email -


Join The Discussion

Contact Desk

Program Enquiry

Drop us an email for Program enquiry

+1 828-214-3944


Sponsors / Exhibiting / Advertising

+1 828-214-3944

Special Issues
All accepted abstracts will be published in respective Allied Academies Journals.
Abstracts will be provided with Digital Object Identifier by

Allied Academies Global Conference Directory

Terms and Conditions

Cancellation, Postponement and Transfer of Registration

All cancellations or modifications of registration must be made in writing to 

Cancellation Policy

If Allied Academies cancels this event for any reason, you will receive a credit for 100% of the registration fee paid. You may use this credit for another Conference Series/OMICS International event which must occur within one year from the date of cancellation.



If Allied Academies postpones an event for any reason and you are unable or unwilling to attend on rescheduled dates, you will receive a credit for 100% of the registration fee paid. You may use this credit for another event which must occur within one year from the date of postponement.


Transfer of registration


All fully paid registrations are transferable to other persons from the same organization, if registered person is unable to attend the event. Transfers must be made by the registered person in writing to . Details must be included the full name of replacement person, their title, contact phone number and email address. All other registration details will be assigned to the new person unless otherwise specified.

Registration can be transferred to one conference to another conference of Allied Academies if the person is unable to attend one of conferences.

However, Registration cannot be transferred if it is intimated within 14 days of respective conference.

The transferred registrations will not be eligible for Refund.


Visa Information

Keeping in view of increased security measures, we would like to request all the participants to apply for Visa as soon as possible.

Allied Academies will not directly contact embassies and consulates on behalf of visa applicants. All delegates or invitees should apply for Business Visa only.

Important note for failed visa applications: Visa issues cannot come under the consideration of cancellation policy of Allied Academies, including the inability to obtain a visa.

Refund Policy

If the registrant is unable to attend, and is not in a position to transfer his/her participation to another person or event, then the following refund arrangements apply:

Keeping in view of advance payments towards Venue, Printing, Shipping, Hotels and other overheads, we had to keep Refund Policy is as following slabs-

  • Before 60 days of the conference: Eligible for Full Refund less $100 service Fee
  • Within 60-30 days of Conference: Eligible for 50% of payment Refund
  • Within 30 days of Conference: Not eligible for Refund
  • E-Poster Payments will not be refunded.

Accommodation Cancellation Policy


Accommodation Providers (Hotels) have their own cancellation policies, and they generally apply when cancellations are made less than 30 days prior to arrival. Please contact us as soon as possible, if you wish to cancel or amend your accommodation. Allied Academies will advise the cancellation policy of your accommodation provider, prior to cancelling or amending your booking, to ensure you are fully aware of any non-refundable deposits.



Highlights from last year's Convention

Copyright © 2019-2020 Allied Academies, All Rights Reserved.